ImpediMed (IPD) Stock Overview
A medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IPD Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ImpediMed Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.005 |
| 52 Week High | AU$0.059 |
| 52 Week Low | AU$0.005 |
| Beta | 1.09 |
| 1 Month Change | -16.67% |
| 3 Month Change | -66.67% |
| 1 Year Change | -86.49% |
| 3 Year Change | -97.30% |
| 5 Year Change | -95.24% |
| Change since IPO | -99.41% |
Recent News & Updates
IPD: Expanded Breast Cancer Care Vision Will Support Future Equity-Funded Upside
Analysts have revised their price target for ImpediMed from A$0.13 to A$0.06, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for ImpediMed ImpediMed has scheduled a Special and Extraordinary Shareholders Meeting for June 11, 2026 at 11:00 E.
IPD: Equity Raise And New CEO Will Support Future Rebound
Analysts have revised their ImpediMed valuation, with the fair value estimate moving from A$0.10 to A$0.03 as they apply a higher discount rate, assume slightly lower revenue growth, factor in a higher profit margin, and use a much lower future P/E multiple in their models. What's in the News for ImpediMed ImpediMed scheduled a Special and Extraordinary Shareholders Meeting for June 11, 2026, at Clifford Chance in Sydney, to seek investor approval for multiple share, option, and follow on option issuances across placement tranches, a share purchase plan, Trafalgar Capital, and Christine Emmanuel Donnelly or nominee.Recent updates
IPD: Expanded Breast Cancer Care Vision Will Support Future Equity-Funded Upside
Analysts have revised their price target for ImpediMed from A$0.13 to A$0.06, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for ImpediMed ImpediMed has scheduled a Special and Extraordinary Shareholders Meeting for June 11, 2026 at 11:00 E.IPD: Equity Raise And New CEO Will Support Future Rebound
Analysts have revised their ImpediMed valuation, with the fair value estimate moving from A$0.10 to A$0.03 as they apply a higher discount rate, assume slightly lower revenue growth, factor in a higher profit margin, and use a much lower future P/E multiple in their models. What's in the News for ImpediMed ImpediMed scheduled a Special and Extraordinary Shareholders Meeting for June 11, 2026, at Clifford Chance in Sydney, to seek investor approval for multiple share, option, and follow on option issuances across placement tranches, a share purchase plan, Trafalgar Capital, and Christine Emmanuel Donnelly or nominee.We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Shareholder Returns
| IPD | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -16.7% | -4.6% | -0.3% |
| 1Y | -86.5% | -43.8% | 2.0% |
Return vs Industry: IPD underperformed the Australian Medical Equipment industry which returned -43.8% over the past year.
Return vs Market: IPD underperformed the Australian Market which returned 2% over the past year.
Price Volatility
| IPD volatility | |
|---|---|
| IPD Average Weekly Movement | 24.3% |
| Medical Equipment Industry Average Movement | 9.7% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.9% |
Stable Share Price: IPD's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: IPD's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 77 | Erik Anderson | www.impedimed.com |
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.
ImpediMed Limited Fundamentals Summary
| IPD fundamental statistics | |
|---|---|
| Market cap | AU$14.03m |
| Earnings (TTM) | -AU$24.37m |
| Revenue (TTM) | AU$14.23m |
Is IPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPD income statement (TTM) | |
|---|---|
| Revenue | AU$14.23m |
| Cost of Revenue | AU$1.97m |
| Gross Profit | AU$12.26m |
| Other Expenses | AU$36.63m |
| Earnings | -AU$24.37m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 86.14% |
| Net Profit Margin | -171.25% |
| Debt/Equity Ratio | 231.3% |
How did IPD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/14 15:55 |
| End of Day Share Price | 2026/07/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImpediMed Limited is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Williamson | Bell Potter |
| Martyn Jacobs | Bell Potter |
| Shane Storey | Canaccord Genuity |